XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2021
Feb. 28, 2019
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement     $ 38,505,000 $ 20,988,000 $ 76,947,000 $ 41,898,000
Revenue recognized $ 40,600,000       (47,883,000)  
Development Revenue            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement     19,950,000 13,003,000 43,218,000 24,444,000
MRD Development Agreements            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement     2,600,000   3,200,000  
Milestone revenue recognized     1,500,000   8,500,000  
Revenue recognized     2,300,000   9,500,000  
MRD Development Agreements | Maximum            
Disaggregation Of Revenue [Line Items]            
Additional milestone payment receivable 327,000,000.0   327,000,000.0   327,000,000.0  
MRD Development Agreements | Development Revenue            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement     300,000   300,000  
Revenue recognized       100,000   500,000
Genentech Collaboration Agreement            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement     17,200,000 $ 12,700,000 32,800,000 $ 23,600,000
Non-refundable upfront payments received   $ 300,000,000.0     $ 300,000,000.0  
Genentech Collaboration Agreement | Maximum            
Disaggregation Of Revenue [Line Items]            
Revenue recognition expected period         8 years  
Genentech Collaboration Agreement | Maximum | Regulatory Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 75,000,000.0   75,000,000.0   $ 75,000,000.0  
Genentech Collaboration Agreement | Maximum | Development Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 300,000,000.0   300,000,000.0   300,000,000.0  
Genentech Collaboration Agreement | Maximum | Commercial Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 1,430,000,000.0   1,430,000,000.0   1,430,000,000.0  
Genentech Collaboration Agreement | Minimum            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments $ 1,800,000   $ 1,800,000   $ 1,800,000  
Revenue recognition expected period         7 years